13F filer · CIK 1697748 ↗
ARK Invest
You are looking at Q2 2019. See the latest, Q2 2026 →
Reported value
$3.97B
+13% on the quarter before
Positions
229
53 new · 20 sold out
Top 10
50.0%
of the value
Est. gain
+$31.2M
on stocks held all quarter
Est. return
+1.1%
on those stocks since Q1 2019
Positions as of Jun 30, 2019, from ARK Invest's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q1 2019. Striped tiles are options.
Largest buys
Since Q1 2019, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Lendingclub Corp~$338.8MNew · 0.0% → 8.5%+20,659,636 shares
- Tesla~$91.5MAdded · 6.0% → 6.5%+409,332 shares
- Xilinx Inc~$43.5MAdded · 0.4% → 1.4%+368,657 shares
- 2u Inc~$33.4MAdded · 1.0% → 1.3%+886,408 shares
- Crispr Therapeutics Ag~$33.0MAdded · 2.1% → 3.2%+701,332 shares
- Pluristem Therapeutics Inc~$32.0MNew · 0.0% → 0.8%+5,156,645 shares
- Nutanix~$31.8MAdded · 0.2% → 0.9%+1,224,081 shares
- Meta~$31.4MNew · 0.0% → 0.8%+162,707 shares
- Block~$27.1MAdded · 4.6% → 4.6%+373,765 shares
- Illumina Inc~$26.0MAdded · 4.1% → 5.0%+70,578 shares
Largest sells
Since Q1 2019, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Medidata Solutions Inc~$100.5MCut · 2.3% → 0.0%−1,111,222 shares
- Lendingclub Corp~$66.3MSold out · 1.9% → 0.0%−21,453,157 shares
- Twitter Inc~$50.0MCut · 4.4% → 2.8%−1,432,499 shares
- Lendingtree Inc~$49.3MCut · 2.2% → 1.0%−117,292 shares
- Baidu~$39.2MCut · 4.5% → 1.9%−333,927 shares
- Nvidia~$35.7MCut · 6.6% → 4.4%−217,650 shares
- Teradyne~$27.1MCut · 2.2% → 1.6%−566,400 shares
- Netflix~$27.1MCut · 1.9% → 1.1%−73,747 shares
- Apple~$26.3MCut · 1.2% → 0.4%−132,634 shares
- Tencent Holdings Ltd-Uns ADR~$21.6MCut · 3.0% → 2.0%−476,975 shares
Holdings
As of Jun 30, 2019. Changes are in shares against Mar 31, 2019, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Lendingclub CorpCommon Stock · shares New | 8.5% | $338.8M | — | ||||||||
| TeslaCommon Stock · shares +54% · price −20.2% | 6.5% | $259.9M | −$42.5M | ||||||||
| Stratasys LtdCommon Stock · shares +6.2% · price +23.3% | 5.7% | $226.5M | +$40.3M | ||||||||
| Invitae CorpCommon Stock · shares +7.9% · price +0.3% | 5.6% | $221.4M | +$698,615 | ||||||||
| Illumina IncCommon Stock · shares +15% · price +18.5% | 5.0% | $197.9M | +$26.8M | ||||||||
| BlockCommon Stock · shares +18% · price −3.2% | 4.6% | $181.8M | −$5.1M | ||||||||
| NvidiaCommon Stock · shares −17% · price −8.5% | 4.4% | $176.0M | −$16.4M | ||||||||
| Intellia Therapeutics IncCommon Stock · shares +3.3% · price −4.2% | 3.4% | $134.9M | −$5.7M | ||||||||
| Crispr Therapeutics AgCommon Stock · shares +35% · price +31.9% | 3.2% | $128.3M | +$23.0M | ||||||||
| Editas Medicine IncCommon Stock · shares +6.3% · price +1.2% | 3.0% | $119.9M | +$1.3M | ||||||||
| Twitter IncCommon Stock · shares −31% · price +6.1% | 2.8% | $112.7M | +$6.5M | ||||||||
| Nanostring Technologies IncCommon Stock · shares +1.4% · price +26.8% | 2.7% | $107.0M | +$22.3M | ||||||||
| Veracyte IncCommon Stock · shares −12% · price +13.9% | 2.2% | $86.6M | +$10.6M | ||||||||
| Tencent Holdings Ltd-Uns ADRADR · shares −21% · price −1.6% | 2.0% | $80.1M | −$1.3M | ||||||||
| BaiduADR · shares −35% · price −28.8% | 1.9% | $74.2M | −$30.0M | ||||||||
| Spotify Technology SaCommon Stock · shares +8.9% · price +5.3% | 1.8% | $72.6M | +$3.4M | ||||||||
| Zillow Group Inc - CCommon Stock · shares −22% · price +33.5% | 1.8% | $72.4M | +$18.2M | ||||||||
| Teladoc IncCommon Stock · shares +33% · price +19.4% | 1.6% | $64.9M | +$8.0M | ||||||||
| TeradyneCommon Stock · shares −30% · price +20.3% | 1.6% | $63.8M | +$10.8M | ||||||||
| Splunk IncCommon Stock · shares +20% · price +0.9% | 1.6% | $63.8M | +$485,137 | ||||||||
| SalesforceCommon Stock · shares +19% · price −4.2% | 1.6% | $62.6M | −$2.3M | ||||||||
| Xilinx IncCommon Stock · shares +362% · price −7.0% | 1.4% | $55.5M | −$904,907 | ||||||||
| Proto Labs IncCommon Stock · shares +62% · price +10.3% | 1.4% | $54.6M | +$3.2M | ||||||||
| Materialise Nv-ADRADR · shares +1.6% · price +24.0% | 1.4% | $54.5M | +$10.4M | ||||||||
| 2u IncCommon Stock · shares +171% · price −46.9% | 1.3% | $52.8M | −$17.2M | ||||||||
| Total · 229 positions | 100% | $3.97B | +$31.2M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q1 2019 to Q2 2019: 167 stocks held throughout, up $31.2M (+1.1%).
- Stratasys Ltd+$40.3M+23%
- Illumina Inc+$26.8M+18%
- Crispr Therapeutics Ag+$23.0M+32%
- Nanostring Technologies Inc+$22.3M+27%
- Zillow Group Inc - C+$18.2M+34%
- Nvidia−$16.4M−9%
- 2u Inc−$17.2M−47%
- Seres Therapeutics Inc−$19.3M−53%
- Baidu−$30.0M−29%
- Tesla−$42.5M−20%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out, 2 splits read into the share counts.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 14, 2026 | $15.40B+20% | SEC ↗ |
| Q1 2026 | May 12, 2026 | $12.86B−15% | SEC ↗ |
| Q4 2025 | Feb 11, 2026 | $15.07B−10% | SEC ↗ |
| Q3 2025 | Nov 12, 2025 | $16.80B+23% | SEC ↗ |
| Q2 2025 | Jul 30, 2025 | $13.64B+37% | SEC ↗ |
| Q1 2025 | May 7, 2025 | $9.99B−17% | SEC ↗ |
| Q4 2024 | Feb 4, 2025 | $12.01B+10% | SEC ↗ |
| Q3 2024 | Oct 31, 2024 | $10.93B−3% | SEC ↗ |
| Q2 2024 | Jul 26, 2024 | $11.27B−22% | SEC ↗ |
| Q1 2024 | Apr 18, 2024 | $14.44B−14% | SEC ↗ |
| Q4 2023 | Jan 17, 2024 | $16.89B+29% | SEC ↗ |
| Q3 2023 | Oct 18, 2023 | $13.07B−13% | SEC ↗ |
| Q2 2023 | Jul 10, 2023 | $15.10B+4% | SEC ↗ |
| Q1 2023 | Apr 17, 2023 | $14.55B+26% | SEC ↗ |
| Q4 2022 | Jan 24, 2023 | $11.54B−20% | SEC ↗ |
| Q3 2022 | Oct 17, 2022 | $14.35B−15% | SEC ↗ |
| Q2 2022 | Jul 11, 2022 | $16.91B−29% | SEC ↗ |
| Q1 2022 | Apr 18, 2022 | $23.96B−28% | SEC ↗ |
| Q4 2021 | Jan 28, 2022 | $33.08B−21% | SEC ↗ |
| Q3 2021 | Nov 12, 2021 | $41.64B−23% | SEC ↗ |
| Q2 2021 | Aug 5, 2021 | $53.74B+7% | SEC ↗ |
| Q1 2021 | May 13, 2021 | $50.34B+34% | SEC ↗ |
| Q4 2020 | Feb 12, 2021 | $37.59B+123% | SEC ↗ |
| Q3 2020 | Oct 30, 2020 | $16.86B+81% | SEC ↗ |
| Q2 2020 | Aug 11, 2020 | $9.30B+132% | SEC ↗ |
| Q1 2020 | May 14, 2020 | $4.01B+1% | SEC ↗ |
| Q4 2019 | Jan 31, 2020 | $3.96B−13% | SEC ↗ |
| Q3 2019 | Nov 12, 2019 | $4.58B+15% | SEC ↗ |
| Q2 2019 | Jul 30, 2019 | $3.97B+13% | SEC ↗ |
| Q1 2019 | May 13, 2019 | $3.50B+42% | SEC ↗ |
| Q4 2018 | Feb 11, 2019 (amended) | $2.46B−26% | SEC ↗ |
| Q3 2018 | Nov 7, 2018 | $3.31B+21% | SEC ↗ |
| Q2 2018 | Aug 7, 2018 | $2.73B+36% | SEC ↗ |
| Q1 2018 | May 14, 2018 | $2.01B+60% | SEC ↗ |
| Q4 2017 | Feb 12, 2018 | $1.26B+53% | SEC ↗ |
| Q3 2017 | Nov 9, 2017 | $819.3M+60% | SEC ↗ |
| Q2 2017 | Aug 11, 2017 | $513.6M+48% | SEC ↗ |
| Q1 2017 | May 15, 2017 | $346.9M+26% | SEC ↗ |
| Q4 2016 | Feb 13, 2017 | $274.9M | SEC ↗ |